RxDoctor Payments Data

William Bartlett, MD

Ophthalmology · Santa Rosa, CANPI 1881680171

Payments from drug & device makers

$13,680in general payments, 2019–2025

Across 56 payments — averaging $244.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$13K
  • AbbVie$244
  • Biotissue Holdings Inc.$183
  • Alcon$120
  • Oyster Point Pharma, Inc.$106
  • Bausch & Lomb Americas Inc.$77
  • plus $411 from 10 others

What the payments were for

  • Food & beverage$1,09094%
  • Gifts$756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,680 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$858,155
Medicare patients
2,441
Services billed
6,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine40$61,952
LumiganBimatoprost67$43,582
Prednisolone Acetate619$23,482
Latanoprost1,043$18,555
RhopressaNetarsudil Mesylate28$15,833
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat300$8,908
VyzultaLatanoprostene Bunod15$8,431
Timolol Maleate607$8,095
Cyclosporine18$7,977
Travoprost30$5,978
SimbrinzaBrinzolamide/Brimonidine Tart21$5,741
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$3,294
Brimonidine Tartrate89$1,885
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha91$1,084
ValacyclovirValacyclovir Hcl18$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$244$105,534107 claims
Aerie Pharmaceuticals, Inc.Rhopressa$45$15,83328 claims
Bausch & Lomb Americas Inc.Vyzulta$77$8,43115 claims
AlconSimbrinza$120$5,74121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →